Understanding how tumors respond to radiation therapy
Official title: Shared Resource Core 1: Molecular Data Science and Advanced Dosimetry
Funded at Dana-Farber Cancer Inst · NIH-10931445 · Data updated 2026-11-12
This study is looking at how certain childhood tumors, like diffuse midline gliomas and neuroblastoma, respond to radiation therapy, using advanced technology to find out why some tumors resist treatment, with the goal of improving care for kids facing these tough cancers.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $186,732 |
| NIH project number | 5U54CA274516-02 |
| Project ID | NIH-10931445 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children diagnosed with diffuse midline gliomas or neuroblastoma who are undergoing or considering radiation therapy.
✕Less likely to help
Patients with other types of cancers or those not receiving radiation therapy may not benefit from this research.
What this research studies
This research investigates the response of pediatric tumors, specifically diffuse midline gliomas and neuroblastoma, to radiation therapy by analyzing the molecular data and tumor microenvironment. It utilizes advanced data science and artificial intelligence to identify factors that contribute to tumor resistance and response to treatment. The project aims to create a comprehensive data hub for managing and analyzing molecular data, which will help in understanding the complexities of tumor behavior during radiotherapy. By integrating various data types, the research seeks to improve treatment strategies for these challenging cancers.
Why it matters
Potential benefit: If successful, this research could lead to more effective radiation therapies for pediatric cancers, improving survival rates and quality of life for young patients.
How similar studies have gone: Previous research has shown promise in using data science and AI to enhance cancer treatment strategies, indicating that this approach could yield significant advancements.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Michor, Franziska — Dana-Farber Cancer Inst
- Study coordinator: Michor, Franziska
Related research
Other NIH-funded projects on the same topics.
-
Helping young people with cancer understand their genetic risks
This study is creating a special program to help teenagers and young adults with hereditary cancer risks learn about their health and make smart choices, while also supporting their families along the way.
-
Core administrative hub for a multifaceted cancer center program
A large, international cancer research program at Dana-Farber aims to advance a curative strategy for multiple myeloma by coordinating translational research, clinical trials, and data analysis.
-
Automated, interactive lab tool to define radiation targets in cancer care
Aims to make it easier and safer to outline the area to treat in radiation therapy for cancers by using smart software and a patient-friendly interface.
-
Cancer Atlas Network data hub to share big cancer data
A national project helps researchers store, harmonize, and share large cancer data collections so doctors and scientists can learn from many patients.
-
Bridge-building cancer research partnership for education, outreach, and science
A joint effort between UMass Boston and Harvard Cancer Consortium to accelerate cancer research and education by connecting lower-resourced institutions with a leading cancer center.
-
NexTGen: Next-Generation T cell therapy for childhood cancers
A charity-friendly overview: researchers at Dana-Farber are developing advanced engineered T-cell therapies to treat pediatric solid cancers like brain tumors and sarcomas.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.